STUDY OF CHANGES IN TUMOR BLOOD FLOW FOR THE ASSESSMENT OF EARLY RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS

Author:

Pavlov M. V.1,Rykhtik P. I.2,Ilyinskaya O. E.3,Subochev P. V.4,Kreinina Yu. M.5,Maslennikova A. V.6ORCID

Affiliation:

1. Nizhny Novgorod Regional clinical oncology dispensary; Privolzhsky Research Medical University

2. Volga Region Medical Center

3. Nizhny Novgorod Regional Clinical Oncology Dispensary

4. Institute of Applied Physics RAS

5. Russian Scientific Center of Roentgenoradiology

6. Privolzhsky Research Medical University

Abstract

Background. Over the past 20 years, there has been a change in approaches to the treatment of breast cancer, in particular, a significant increase in the role of drug therapy. Breast cancer response to neoadjuvant chemotherapy is currently considered as a surrogate biomarker, which allows evaluation of the clinical course and prognosis of the disease. To solve this problem, it is necessary to assess the functional and metabolic changes in tumor tissue during treatment. Doppler ultrasound is a non-invasive, affordable, and low-cost imaging technique that can be safely used for repeated measurements.The purpose of the study was to study vascular changes in the tumor by power Doppler ultrasound for the evaluation of the early breast cancer response to neoadjuvant chemotherapy.Material and Methods. From May 2017 to August 2019, 63 patients with breast cancer received neoadjuvant chemotherapy. Changes in the tumor blood flow were assessed before starting the treatment and prior to the second course of neoadjuvant chemotherapy using Doppler scanning. Changes in tumor blood floor after chemotherapy were compared with the pathological tumor response after surgical treatment.Results. In the vast majority of cases (78 %), there was a decrease in the number of tumor vessels after the first cycle of neoadjuvant chemotherapy independent of the grade of pathological response. In 8 cases with increased vascularization after the first cycle of neoadjuvant chemotherapy, histological examination of the removed tumor showed no response / weak response to treatment in the absence of peritumoral inflammation. In 5 cases, a sharp increase in the number of vessels around large areas of intranodular necrosis and peritumoral inflammation was observed. In general, a comparison of changes in tumor vascularization and pathological response revealed a weak, although statistically significant, negative correlation between changes in the tumor blood flow after neoadjuvant chemotherapy and pathological response.Conclusion. It was not possible to establish an unambiguous relationship between the reaction of the vascular bed and the tumor response to the cytostatic effect. An increase in the number of tumor vessels in the absence of peritumoral inflammation was the only situation when changes in tumor blood flow during chemotherapy can be unambiguously interpreted as a predictive criterion for the absence / weak response of the tumor to treatment.

Publisher

Tomsk Cancer Research Institute

Subject

Cancer Research,Oncology

Reference35 articles.

1. World health organization [Internet]. URL: http://www.who.int/en/ (cited 07.03.2020).

2. Fisher B. Laboratory and clinical research in breast cancer-- a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res. 1980 Nov; 40(11): 3863–74.

3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R., Davies C., Godwin J., Gray R., Pan H.C., Clarke M., Cutter D., Darby S., McGale P., Taylor C., Wang Y.C., Bergh J., Di Leo A., Albain K., Swain S., Piccart M., Pritchard K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012; 379(9814): 432–44. doi: 10.1016/S0140-6736(11)61625-5.

4. Waljee J.F., Newman L.A. Neoadjuvant systemic therapy and the surgical management of breast cancer. Surg Clin North Am. 2007 Apr; 87(2): 399–415, ix. doi: 10.1016/j.suc.2007.02.004.

5. Cortazar P., Zhang L., Untch M., Mehta K., Costantino J.P., Wolmark N., Bonnefoi H., Cameron D., Gianni L., Valagussa P., Swain S.M., Prowell T., Loibl S., Wickerham D.L., Bogaerts J., Baselga J., Perou C., Blumenthal G., Blohmer J., Mamounas E.P., Bergh J., Semiglazov V., Justice R., Eidtmann H., Paik S., Piccart M., Sridhara R., Fasching P.A., Slaets L., Tang S., Gerber B., Geyer C.E.Jr., Pazdur R., Ditsch N., Rastogi P., Eiermann W., von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul; 384(9938): 164–72. doi: 10.1016/S0140-6736(13)62422-8.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3